Trametinib
| Status | Pipeline |
| Development phase | Under development |
| Therapeutic cat. | Oncology |
| Polymorphic form | DMSO solvate |
| CAS No. | 871700-17-3 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | 5 |
| Samples | Q4 2024 |
Drug description
Trametinib is used, either alone or in combination with dabrafenib to treat certain types of cancer of the skin, lung, or thyroid. Trametinib is also used to treat solid tumors in adults and children at least 6 years old. Trametinib is also used to treat a type of brain tumor called low grade glioma in adults and children at least 1 years old.Trametinib is often given when the cancer has spread to other parts of the body, when surgery is not an option, or to keep the cancer from coming back after surgery.
Polpharma API
- Samples availabilty: Q4 2024
- Cost- and time-efficient manufacturing process carried out in a brand-new innovative facility with state-of-art equipment
- Tailor-made PSD
- European API manufacturer
- Production facility suitable for ANVISA requirements
- High back integration: 12 steps in house, to allow high control over the process
Disclaimer
Trametinib is protected by patents (SPC) in Poland and is developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. Trametinib is not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
